Background In a phase 2 trial, lenvatinib, an inhibitor of VEGF receptors 1–3, FGF receptors
1–4, PDGF receptor α, RET, and KIT, showed activity in hepatocellular carcinoma. We aimed …

Sorafenib has been the standard therapy for patients with unresectable hepatocellular
carcinoma (HCC) since 2007, when it was shown to prolong survival, as verified in the …

4074 Background: The PI3K/Akt/mTOR pathway, a key regulator of cellular proliferation and
angiogenesis, has emerged as a contributor to hepatocarcinogenesis. Everolimus, an …

Hepatocellular carcinoma (HCC) is the fifth most common primary cancer and second
largest cause of cancer‐related death worldwide. The first‐line oral chemotherapeutic agent …

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and is associated
with high mortality rate. Incidence remains high due to the persistent prevalence of viral …

Simple Summary Approximately 80% hepatocellular carcinoma (HCC) patients are in
intermediate or advanced stages at diagnosis and have lost the chance of curative surgery …

Background and aims: Prospective randomized trials have proven that sorafenib is a valid
treatment option for patients with advanced-stage hepatocellular carcinoma (HCC). The aim …

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Patients
commonly present with advanced/unresectable HCC where several treatment options are …

To investigate efficacy and safety of hepatic arterial infusion chemotherapy combined with
lenvatinib (HAIC-Len) and HAIC alone for the treatment of advanced hepatocellular …

Background & Aims Sorafenib is the only therapy shown to improve overall survival in
advanced hepatocellular carcinoma (HCC). Combination therapy targeting multiple …